John Carroll, founder and editor of Endpoints News, with Sebastian Guth, Bayer Pharmaceuticals' president for the Americas, at an Endpoints News event in San Diego on June 14, 2022

Con­nect with End­points News — here's our ma­jor event cal­en­dar com­ing up in H2 2022

The room was packed and elec­tric. That’s how it felt host­ing an event in per­son for End­points News read­ers last month in San Diego.

It ex­ceed­ed all our ex­pec­ta­tions, which wasn’t a giv­en, with the pan­dem­ic chang­ing the na­ture of live events. We hadn’t done one in over two years. And End­points grew a lot dur­ing that time. We quick­ly built a se­ri­ous vir­tu­al events plat­form and de­vel­oped big au­di­ences around those on­line chan­nels. But there’s noth­ing quite like be­ing with your col­leagues at a live event. End­points has a tra­di­tion of con­ven­ing our au­di­ence of bio­phar­ma pros in ma­jor hubs world­wide since our start in 2016. And we’re thrilled to jump right back in.

With a wrap on BIO, AS­CO, Cannes and oth­er crit­i­cal in­dus­try mee­tups, there are sev­er­al key dates ahead on the End­points cal­en­dar to at­tend — both live and in-per­son. And spon­sor­ship op­por­tu­ni­ties re­main for bio­phar­ma mar­keters. Here’s what’s on deck:

Ma­jor End­points events

The End­points 11 (Sep­tem­ber 22, Boston) — Big dreams dom­i­nate among next-gen biotech play­ers. Our an­nu­al E11 se­ries is back to hon­or the up­starts most poised for im­pact — an event that al­so marks John Car­roll’s 20th year spot­light­ing pri­vate biotechs. Join us vir­tu­al­ly or in per­son at an ex­clu­sive event in Boston. Past events: 2021, 2020 | Cov­er­age: 2021, 2020

#EU­BIO22 (Oc­to­ber 12, Lon­don) — The bio­phar­ma view from the con­ti­nent. Read­ers can sign up to stream the full line­up — or pur­chase a tick­et to join us in Lon­don that af­ter­noon — as John Car­roll and Sil­i­con Val­ley Bank’s Nooman Haque host a se­ries of pan­els and fire­side chats as­sess­ing the lat­est M&A, R&D and reg­u­la­to­ry trends fac­ing Eu­rope’s bio­phar­ma in­dus­try.

Women in Bio­phar­ma (De­cem­ber 7, vir­tu­al) — Tak­ing the lead in R&D. You won’t want to miss one of our most pop­u­lar an­nu­al re­ports pro­fil­ing 20 of the in­dus­try’s most in­flu­en­tial women ex­ec­u­tives. Our ed­i­tors will host a spe­cial pre­sen­ta­tion high­light­ing this year’s hon­orees and sub­se­quent pan­el dis­cus­sion prob­ing what’s ahead for di­ver­si­ty and in­clu­sion ini­tia­tives.

Con­fer­ence cov­er­age and events

#ES­MO22 (Sep­tem­ber 12, vir­tu­al) — What’s new in on­col­o­gy in R&D? Our jour­nal­ists will re­port live from Paris with break­ing news and read­outs from the show and re­lease a spe­cial ES­MO re­port on Sep­tem­ber 12. You can al­so tune in live for EIC John Car­roll’s vir­tu­al fire­side with a lead­ing news­mak­er at ES­MO and his sub­se­quent pan­el analy­sis of the con­fer­ence’s biggest wins and loss­es.

#ASH22 (De­cem­ber 12, vir­tu­al) — Cell and gene ther­a­pies are head­ed to crit­i­cal mile­stones. Our glob­al au­di­ence can livestream John Car­roll’s fire­side chat and pan­el re­view un­pack­ing the in­dus­try’s most close­ly watched cell and gene ther­a­pies. If you miss the livestream, you’ll find this year’s spe­cial ASH re­port in your in­box on De­cem­ber 12.

#CPHI (Oc­to­ber 27, spe­cial re­port) — End­points Man­u­fac­tur­ing will have a spe­cial edi­tion cov­er­ing the lat­est in­no­va­tions in phar­ma man­u­fac­tur­ing and de­vel­op­ment in ad­vance of the big CPHI event in Frank­furt.

And, as al­ways, our sum­mer sights are set square­ly in San Fran­cis­co this Jan­u­ary for JP Mor­gan. More to come as we pre­pare for wall-to-wall cov­er­age at the in­dus­try’s pre­mier kick­off event.

For all event ad­ver­tis­ing, sched­ul­ing and pric­ing re­quests, con­tact our sales team di­rec­tors Melis­sa Naz­zaro (melis­sa@end­ and Julie No­tario (jno­tario@end­


For our full me­dia kit, vis­it End­points Stu­dio — our in-house mar­ket­ing agency led by Kari Abit­bol that con­nects bio­phar­ma mar­keters with their tar­get au­di­ences di­rect­ly on the End­points plat­form.

If you want to reach out to the ed­i­to­r­i­al team with sug­ges­tions, email ed­i­tor@end­

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image:

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.